### Wednesday, December 5, 2012

**10:45 a.m. - 11:00 a.m.**  
**Location:** Exhibit Hall D  
**General Session 1:** Program #S1-10 (Oral)  
*Association between the 21-gene Recurrence Score and benefit from adjuvant paclitaxel in node-positive, ER-positive breast cancer patients: Results from NSABP B-28.*

**Contributors:**  

---

**11:00 a.m. - 11:15 a.m.**  
**Location:** Exhibit Hall D  
**General Session 1:** Program #S1-11 (Oral)  
*Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC).*

**Contributors:**  

---

**5:00 p.m. - 7:00 p.m.**  
**Location:** Exhibit Halls A-B  
**Poster Session 1:** Ongoing Trials 1  
**Radiation Therapy**  
Program #OT1-2-01

NSABP B-43: A phase III clinical trial to compare trastuzumab given concurrently with radiation therapy to RT alone for women with HER2+ DCIS resected by lumpectomy.

**Contributors:**  

---

**5:00 p.m. - 7:00 p.m.**  
**Location:** Exhibit Halls A-B  
**Poster Session 1:** Ongoing Trials 1  
**Her2**  
Program #OT1-1-12

NSABP FB-7 trial: A phase II randomized clinical trial evaluating neoadjuvant therapy regimens with weekly paclitaxel and neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer.

**Contributors:**  
Lu J, Jacobs SA, Buyse ME, Paik S, Wolmark N

---

### Thursday, December 6, 2012

**9:45 a.m. - 10:00 a.m.**  
**Location:** Exhibit Hall D  
**General Session 3:** Program #S3-2 (Oral)  
*Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR Trial (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02).*

**Contributors:**  

---

**5:00 p.m. - 7:00 p.m.**  
**Location:** Exhibit Halls A-B  
**Ongoing Trials 3:** Endocrine Therapy  
Program #OT2-2-04

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2-negative breast cancer: SWOG/NSABP S1207.

**Contributors:**  

---

### Friday, December 7, 2012

**10:30 a.m. - 10:45 a.m.**  
**Location:** Exhibit Hall D  
**General Session 5:** Program #S5-5 (Oral)  
*Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.*

**Contributors:**  

---

### Saturday, December 8, 2012

**7:00 a.m. - 8:30 a.m.**  
**Location:** Exhibit Hall C  
**Poster Session 6:** Prognostic and Predictive Factors  
Program #P6-07-06

Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer) trial.

**Contributors:**  